Ionis Pharmaceuticals moves forward with FDA review of donidalorsen for HAE
In a significant development for hereditary angioedema (HAE) patients, Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that the U.S. Food and Drug Administration (FDA) has accepted ... Read More
Ionis Pharmaceuticals to take full ownership of Akcea Therapeutics
Ionis Pharmaceuticals is set to take full ownership of Akcea Therapeutics by acquiring the remaining stake of around 24% in the latter for about $500 ... Read More